<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;fc=2023070 81 14047&amp;ff=20231114090756&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;ff=20231114090756&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 14 日星期二 14:07:57 +0000</lastbuilddate><pubDate> Tue, 14 Nov 2023 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>与男性阻塞性肥厚型心肌病患者相比，Mavacamten 对女性的影响：来自 EXPLORER-HCM 的见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/37961906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>结论：虽然在基线时，参加 EXPLORER-HCM 的有症状梗阻性 HCM 女性比男性年龄更大，心力衰竭和健康状况更差，但使用 mavacamten 治疗在主要和次要 EXPLORER-HCM 终点方面产生了类似的改善，并且在健康状况和 NT-proBNP。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 14 日。doi：10.1161/CIRCULATIONAHA.123.065600。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：与男性相比，患有肥厚型心肌病 (HCM) 的女性心力衰竭发生率更高，预后更差。我们在 EXPLORER-HCM 研究（临床研究评估 Mavacamten [MYK-461] 在患有症状性梗阻性肥厚性心肌病的成人中的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对有症状的阻塞性 HCM 患者中的 mavacamten 与安慰剂进行盲法、随机 EXPLORER-HCM 试验进行预先指定的性别分析。将基线特征与连续变量（表示为平均值）和 χ <sup>2</sup>的<i>t</i>检验进行比较。预先指定的主要、次要和探索性终点以及从基线到治疗结束（第 30 周）的超声心动图测量结果，使用 ANCOVA 分析连续终点，并使用二项式分布的广义线性模型分析二元终点，并进行调整每个结果的基线、纽约心脏协会等级、β-受体阻滞剂的使用和测力计类型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：基线时，女性 (n=102) 年龄较大（62 岁 vs 56 岁； <i>P</i> &lt;0.0001），峰值耗氧量较低（16.7 mL·kg <sup>-1</sup> ·min <sup>-1</sup> vs 21.3 mL·kg <sup>-1</sup> ·min） <sup>-1</sup> ； <i>P</i> &lt;0.0001），更有可能被分配为纽约心脏协会 III 级（42% 对比 17%； <i>P</i> &lt;0.0001），健康状况较差（堪萨斯城心肌病问卷-临床总结评分 64 对比 75； <i>P</i> &lt;0.0001），并且基线血浆 NT-proBNP（N 端 B 型利钠肽原）水平高于男性（n=149）（1704 ng/L 对比 990 ng/L； <i>P</i> =0.004）。在 mavacamten 治疗中，女性和男性在主要复合终点（mavacamten 与安慰剂的百分比差异分别为 22% 和 19%； <i>P</i> = 0.759）和运动后左心室流出量变化的次要终点方面观察到类似的改善束梯度（-42.4 mm Hg 对比 -33.6 mm Hg； <i>P</i> = 0.348），峰值耗氧量变化（1.2 mL·kg <sup>-1</sup> ·min <sup>-1</sup>对比 1.6 mL·kg <sup>-1</sup> ·min <sup>-1</sup> ； <i>P</i> = 0.633） ，以及达到 ≥1 纽约心脏协会等级改善的百分比（41% 对比 28%； <i>P</i> = 0.254）。然而，女性的健康状况改善更大（堪萨斯城心肌病问卷-临床总结评分 14.8 对比 6.1； <i>P</i> = 0.026）以及 NT-proBNP 水平的探索性终点（-1322 ng/L 与 -649 ng/L； <i>P</i> = 0.0008）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：虽然在基线时，参加 EXPLORER-HCM 的有症状梗阻性 HCM 女性比男性年龄更大，心力衰竭和健康状况更差，但使用 mavacamten 治疗在主要和次要 EXPLORER-HCM 终点方面产生了类似的改善，并且在健康状况和 NT-proBNP。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT03470545。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37961906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37961906</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065600>10.1161/CIRCULATIONAHA.123.065600</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37961906</guid><pubDate> Tue, 14 Nov 2023 06:00:00 -0500</pubDate><dc:creator>莎朗·克雷西</dc:creator><dc:creator>理查德·G·巴赫</dc:creator><dc:creator>萨拉·萨贝里</dc:creator><dc:creator>安贾利·T·欧文斯</dc:creator><dc:creator>约翰·斯珀图斯</dc:creator><dc:creator>希拉·M·赫格德</dc:creator><dc:creator>尼尔·拉克达瓦拉</dc:creator><dc:creator>埃斯特·金·尼尔斯</dc:creator><dc:creator>丹尼尔·M·沃伊迪拉</dc:creator><dc:creator>艾米·J·塞纳特</dc:creator><dc:creator>安德鲁·王</dc:creator><dc:date>2023-11-14</dc:date><dc:source>循环</dc:source><dc:title>与男性阻塞性肥厚型心肌病患者相比，Mavacamten 对女性的影响：来自 EXPLORER-HCM 的见解</dc:title><dc:identifier>下午:37961906</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065600</dc:identifier></item><item><title>新型泛 ERR 激动剂通过增强心脏脂肪酸代谢和线粒体功能改善心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37961903/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>结论：ERR 激动剂维持氧化代谢，从而对体内压力超负荷引起的心力衰竭具有心脏保护作用。我们的结果为支持 ERR 激动剂作为新型心力衰竭治疗药物的进一步发展提供了直接的药理学证据。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 14 日。doi：10.1161/CIRCULATIONAHA.123.066542。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：心脏代谢功能障碍是心力衰竭（HF）的一个标志。雌激素相关受体 ERRα 和 ERRγ 是心脏代谢的重要调节因子。因此，激活 ERR 可能是心力衰竭的潜在治疗干预措施。然而，体内研究表明ERR激动剂对于心力衰竭治疗的潜在用途尚不明确，因为尚未获得具有适合体内使用的药代动力学的化合物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：采用基于结构的设计方法，我们设计并合成了 2 种结构不同的泛 ERR 激动剂 SLU-PP-332 和 SLU-PP-915。体内 HF 模型：我们在体内和体外进行了全面的功能、多组学（RNA 测序和代谢组学研究）和遗传依赖性研究，以剖析分子机制、ERR 同工型依赖性和靶点特异性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：SLU-PP-332 和 SLU-PP-915 均显着改善射血分数，改善纤维化，并增加与压力超负荷诱导的心力衰竭相关的生存率，而不影响心脏肥大。ERR 激动剂转录激活广泛的代谢基因，特别是涉及脂肪酸代谢和线粒体功能的基因。代谢组学分析显示，压力超负荷 6 周的小鼠心脏中脂肪酸/脂质和三羧酸/氧化磷酸化代谢物的代谢谱基本正常化。ERR 激动剂增加线粒体氧化能力和脂肪通过体外和体内遗传依赖性实验，我们发现 ERRγ 是 ERR 激动诱导的转录调节和心脏保护的主要介质，并明确证明了靶标特异性。ERR 激动还导致细胞的下调循环和发育途径，部分由心肌细胞中的 E2F1 介导。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：ERR 激动剂维持氧化代谢，从而对体内压力超负荷引起的心力衰竭具有心脏保护作用。我们的结果为支持 ERR 激动剂作为新型心力衰竭治疗药物的进一步发展提供了直接的药理学证据。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37961903/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37961903</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066542>10.1161/CIRCULATIONAHA.123.066542</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37961903</guid><pubDate> Tue, 14 Nov 2023 06:00:00 -0500</pubDate><dc:creator>徐伟毅</dc:creator><dc:creator>西里尔·比永</dc:creator><dc:creator>李慧</dc:creator><dc:creator>安德里亚·维尔德曼</dc:creator><dc:creator>雷奇</dc:creator><dc:creator>安德里亚·格雷夫斯</dc:creator><dc:creator>杰尼·雷·德拉·克鲁兹·里德布</dc:creator><dc:creator>赵元标</dc:creator><dc:creator>马修·海耶斯</dc:creator><dc:creator>于克洋</dc:creator><dc:creator>麦肯纳洛斯比</dc:creator><dc:creator>卡丽莎·S·汉普顿</dc:creator><dc:creator>克里斯蒂娜·M·阿德耶米</dc:creator><dc:creator>洪锡宰</dc:creator><dc:creator>埃莱妮·纳西蒂斯</dc:creator><dc:creator>陈富</dc:creator><dc:creator>泰圭吴</dc:creator><dc:creator>范伟伟</dc:creator><dc:creator>迈克尔·唐斯</dc:creator><dc:creator>瑞安·D·韦尔奇</dc:creator><dc:creator>罗纳德·埃文斯</dc:creator><dc:creator>亚历山大·米洛萨夫列维奇</dc:creator><dc:creator>约翰·K·沃克</dc:creator><dc:creator>布莱恩·C·詹森</dc:creator><dc:creator>裴黎明</dc:creator><dc:creator>托马斯·伯里斯</dc:creator><dc:creator>张立雷</dc:creator><dc:date>2023-11-14</dc:date><dc:source>循环</dc:source><dc:title>新型泛 ERR 激动剂通过增强心脏脂肪酸代谢和线粒体功能改善心力衰竭</dc:title><dc:identifier>下午:37961903</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066542</dc:identifier></item><item><title>一氧化氮通过 CaMKII 的 S-亚硝基化调节 Ca&lt;sup>;2+&lt;/sup>; 渗漏和心律失常</title><link/>https://pubmed.ncbi.nlm.nih.gov/37961889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>结论：我们的结论是，CaMKIIδ 在半胱氨酸 273 上的 S-亚硝基化可以限制随后的 β-肾上腺素能受体诱导的心律失常，但在半胱氨酸 290 上的 S-亚硝基化可能会恶化或维持 β-肾上腺素能受体诱导的心律失常。对临床环境中 NO 供体管理的影响。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 11 月 14 日。doi：10.1161/CIRCRESAHA.123.323571。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：一氧化氮 (NO) 已被确定为心脏 β-肾上腺素能受体刺激过程中产生的信号分子。此外，NO 通过 CaMKIIδ (Ca <sup>2+</sup> /钙调蛋白) 的<i>S-</i>亚硝基化触发自发 Ca <sup>2+</sup>释放。激酶 II δ) 正在兴起。NO 供体因其对心脏的心脏保护作用而在临床上常规使用，但尚不清楚 NO 供体如何调节致心律失常的 CaMKII 来改变心律失常的发生率。我们测试了 CaMKIIδ 的<i>S-</i>亚硝基化在β-肾上腺素能受体刺激之前和期间心脏 Ca <sup>2+</sup>处理和心律失常发生中的半胱氨酸 273 抑制位点和半胱氨酸 290 激活位点。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们测量了来自 C57BL/6J 野生型 (WT) 小鼠和缺乏 CaMKIIδ 表达 (CaMKIIδ-KO) 或缺失 CaMKIIδ 半胱氨酸 273 或半胱氨酸上<i>S-亚</i>硝基化位点的小鼠分离心肌细胞中的 Ca <sup>2+</sup>处理。 -290（CaMKIIδ-C273S 和 -C290A 敲入小鼠）。心肌细胞暴露于 NO 供体、 <i>S-亚</i>硝基谷胱甘肽（GSNO；150 μM）、硝普钠（200 μM）和 β-肾上腺素能激动剂异丙肾上腺素（100 nmol/L） ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：WT 和 CaMKIIδ-KO 心肌细胞均对异丙肾上腺素产生完全正性肌力和松弛性 Ca <sup>2+</sup>瞬时反应，并且 Ca <sup>2+</sup>火花频率增加。然而，CaMKIIδ-KO 中 Ca <sup>2+</sup>火花频率的增加显着减弱。 GSNO 预处理在 WT 心肌细胞中模拟了对异丙肾上腺素诱导的 Ca <sup>2+</sup>火花和波的保护，但在 CaMKIIδ-C273S 心肌细胞中丢失。当异丙肾上腺素后应用 GSNO 时，在 WT 或 CaMKIIδ-C273S 中未观察到这种保护，但在CaMKIIδ-C290A 中明显。在 Langendorff 灌注的离体心脏中，GSNO 预处理限制了 WT 中异丙肾上腺素诱导的心律失常，但不限制 CaMKIIδ-C273S 心脏，而异丙肾上腺素暴露后的 GSNO 会持续或加剧心律失常事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们得出的结论是，CaMKIIδ 在半胱氨酸 273 上的<i>S-亚</i>硝基化可以限制随后的 β-肾上腺素能受体诱导的心律失常，但在半胱氨酸-290 上的<i>S-</i>亚硝基化可能会恶化或维持 β-肾上腺素能受体诱导的心律失常。对临床环境中 NO 供体管理的影响。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37961889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37961889</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323571>10.1161/CIRCRESAHA.123.323571</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37961889</guid><pubDate> Tue, 14 Nov 2023 06:00:00 -0500</pubDate><dc:creator>阿米莉亚·S·鲍尔</dc:creator><dc:creator>埃丝特·阿萨穆多</dc:creator><dc:creator>卢克·皮·沃辛顿</dc:creator><dc:creator>奇德拉·阿利姆</dc:creator><dc:creator>拉克尔·E·帕拉卡尔</dc:creator><dc:creator>雷切尔·华莱士</dc:creator><dc:creator>奥比亚鲁南马 V 埃贝内贝</dc:creator><dc:creator>琼·海勒·布朗</dc:creator><dc:creator>马克·科尔</dc:creator><dc:creator>唐纳德·贝尔斯</dc:creator><dc:creator>杰弗里·埃里克森</dc:creator><dc:date>2023-11-14</dc:date><dc:source>流通研究</dc:source><dc:title>一氧化氮通过 CaMKII 的 S-亚硝基化调节 Ca&lt;sup>;2+&lt;/sup>; 渗漏和心律失常</dc:title><dc:identifier>下午：37961889</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323571</dc:identifier></item><item><title>对心内膜切迹的协同反应揭示了与 Hippo 通路的相互作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37961886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>结论：胚胎心内膜中顺序Notch依赖性转录调控涉及多种因素。Notch通过这些因素激活某些非编码元件，同时抑制可能阻碍心脏瓣膜发育和稳态的元件。Biorxviv：https://www.biorxiv.org/content /10.1101/2023.03.23.533882v1.full。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 11 月 14 日。doi：10.1161/CIRCRESAHA.123.323474。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：心内膜是心脏瓣膜发育和成熟的重要信号中心。基因分析已鉴定出几种人类心内膜基因，其失活会导致二叶式主动脉瓣形成和钙化主动脉瓣疾病，但关于其在瓣膜发育中所起的作用的知识非常有限和疾病由非编码心内膜调节区域和上游因素引起。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们通过与表达 Notch 配体的 OP9 基质细胞短期和长期共培养并抑制 Notch 活性来操纵小鼠胚胎心内膜细胞中的 Notch 信号传导。我们检查了每种条件下的转录谱和染色质可及性情况、整合的转录组学、转录因子占据、染色质可及性和蛋白质组数据集。我们利用 CRISPR-Cas9 编辑的各种非编码调控元件的删除生成了体外和体内模型，并验证了它们的调控潜力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们确定了小鼠胚胎心内膜中对 Notch 配体的初级和次级转录反应，以及瓣膜发育和疾病中依赖于 NOTCH 的转录特征。成人瓣膜中，我们识别了潜在的非编码调节元件，验证了选定的候选元件，提出了相互作用的辅因子，并定义了其调节活性的时间范围。此外，我们通过抑制核 Yap（Yes 相关蛋白）活性发现了与 Hippo 通路的协同转录抑制心脏瓣膜发育过程中的心内膜。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：胚胎心内膜中顺序Notch依赖性转录调控涉及多种因素。Notch通过这些因素激活某些非编码元件，同时抑制可能阻碍心脏瓣膜发育和稳态的元件。Biorxviv：https://www.biorxiv.org/content /10.1101/2023.03.23.533882v1.full。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37961886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37961886</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323474>10.1161/CIRCRESAHA.123.323474</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37961886</guid><pubDate> Tue, 14 Nov 2023 06:00:00 -0500</pubDate><dc:creator>路易斯·卢纳-苏里塔</dc:creator><dc:creator>布伦达·吉赛尔·弗洛雷斯-加尔萨</dc:creator><dc:creator>迪米特里奥斯·格里瓦斯</dc:creator><dc:creator>马科斯·西格罗·阿尔瓦雷斯</dc:creator><dc:creator>何塞·路易斯·德拉庞帕</dc:creator><dc:date>2023-11-14</dc:date><dc:source>流通研究</dc:source><dc:title>对心内膜切迹的协同反应揭示了与 Hippo 通路的相互作用</dc:title><dc:identifier>下午：37961886</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323474</dc:identifier></item><item><title>破坏细胞特异性 miRNA-CXCR4 相互作用对小鼠具有动脉粥样硬化保护作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 11 月 13 日。doi：10.1038/s41569-023-00959-y。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37957335</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00959-y>10.1038/s41569-023-00959-y</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37957335</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>艾琳·费尔南德斯-鲁伊斯</dc:creator><dc:date>2023-11-13</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>破坏细胞特异性 miRNA-CXCR4 相互作用对小鼠具有动脉粥样硬化保护作用</dc:title><dc:identifier>下午:37957335</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00959-y</dc:identifier></item><item><title>缺血试验中冠状动脉血运重建模式的结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>结论：在缺血中，与 CON 相比，通过 PCI 和 CABG 进行早期血运重建与较高的早期风险和较低的心血管事件长期风险相关。由于方案定义的程序性心肌梗死，CABG 后的早期风险最大。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 11 月 8 日：S0735-1097(23)07988-3。doi：10.1016/j.jacc.2023.11.002。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在 ISCHEMIA 试验中，稳定型冠状动脉疾病患者的缺血事件风险通过血管造影和经皮 (PCI) 或手术 (CABG) 冠状动脉血运重建的侵入性 (INV) 策略和保守 (CON) 策略进行治疗。初步药物治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：分别分析接受 PCI 或 CABG 治疗的 INV 患者的结局。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从血运重建时起，没有发生主要结局事件的患者被分类为 INV-PCI 或 INV-CABG。缺血性主要结局（心血管死亡、方案定义的心肌梗死 (MI) 或因不稳定心绞痛住院、心力衰竭的综合结果）或复苏的心脏骤停）被使用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 INV-CABG 患者中，中位随访 2.85 年时，84/512 例 (16.4%) 发生主要结局事件；CABG 后 30 天内发生 48 例事件 (57.1%)，其中包括 40 例手术性心肌梗死；INV-CABG 患者中PCI 患者中，中位随访 2.94 年时，主要结局事件发生率为 147/1500 (9.8%)；其中 31 例 (21.1%) 在 PCI 后 30 天内发生，包括 23 例手术性 MI。相比之下，352/2591 例 (13.6) %) CON 患者在中位随访 3.2 年时出现主要结局事件，其中 22 例 (6.3%) 在随机分组后 30 天内发生。在 CABG 和 PCI 之后，调整后的主要结局风险 (HR [95%CI]) 较高30 天（16.25（11.44-23.07）和 2.99（1.97-4.53））以及此后更低（0.63（0.44-0.89）和 0.66（0.53-0.82））。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在缺血中，与 CON 相比，通过 PCI 和 CABG 进行早期血运重建与较高的早期风险和较低的心血管事件长期风险相关。由于方案定义的程序性心肌梗死，CABG 后的早期风险最大。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956961</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.11.002>10.1016/j.jacc.2023.11.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956961</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>比约恩·雷德福斯</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:creator>约翰·H·亚历山大</dc:creator><dc:creator>埃里克·R·贝茨</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>朱塞佩·比昂迪·佐卡伊</dc:creator><dc:creator>图利奥·卡尔多纳佐</dc:creator><dc:creator>迈克尔·法库</dc:creator><dc:creator>穆罕默德·拉胡马</dc:creator><dc:creator>约翰·普斯卡什</dc:creator><dc:creator>西格丽德·桑德纳</dc:creator><dc:creator>马里奥·弗尔·高迪诺</dc:creator><dc:date>2023-11-13</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>缺血试验中冠状动脉血运重建模式的结果</dc:title><dc:identifier>下午:37956961</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.11.002</dc:identifier></item><item><title>动态心电图变化是心源性猝死的新风险标志</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>结论：动态心电图重塑改善了 SCD 风险预测，超越了临床因素与静态心电图相结合的结果，并在不同地理区域的人群中成功进行了验证。这些发现引入了 SCD 动态风险的新概念，值得进一步详细研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 13 日：ehad770。doi：10.1093/eurheartj/ehad770。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：心电图异常已被评估为心源性猝死（SCD）的静态风险标记，但动态心电图重塑的潜在重要性尚未得到研究。在本研究中，动态心电图重塑的性质和患病率在以下个体中进行了研究：最终患上SCD。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：研究人群选自美国俄勒冈州（2002 年-，发现队列）和美国加利福尼亚州（2015 年-，验证队列）的两项前瞻性社区 SCD 研究。对于本次研究，231 个发现病例（2015 年） -2017 年）和 203 个验证病例（2015-2021 年）具有 ≥2 个存档的 SCD 前心电图，并根据年龄、性别和心电图之间的持续时间与 234 个发现对照和 203 个验证对照相匹配。测量动态心电图重塑作为先前验证的累积 6 变量心电图电风险评分 (ERS) 的进展。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：俄勒冈州 SCD 病例与对照相比，随着时间的推移显示出更大的 ERS ​​增加 [+1.06（95% CI +0.89 至 +1.24）对比 -0.05（-0.21 至 +0.11）；p &lt; 0.001]。这些发现在加利福尼亚州 [+0.87（+0.7 至 +1.04）对比 -0.11（-0.27 至 0.05）；p &lt; 0.001]。在多变量模型中，异常动态心电图重构改善了 SCD 预测，优于基线心电图、人口统计学和临床​​ SCD 危险因素俄勒冈州 [AUC 0.770 (95% CI 0.727-0.812) 增加至 AUC 0.869 (95% CI 0.837-0.902)] 和加利福尼亚州队列。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：动态心电图重塑改善了 SCD 风险预测，超越了临床因素与静态心电图相结合的结果，并在不同地理区域的人群中成功进行了验证。这些发现引入了 SCD 动态风险的新概念，值得进一步详细研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956651</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad770>10.1093/eurheartj/ehad770</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956651</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>范汉恩</dc:creator><dc:creator>霍尔姆斯特罗姆</dc:creator><dc:creator>H楚格</dc:creator><dc:creator>乌伊·埃瓦纳多</dc:creator><dc:creator>K中村</dc:creator><dc:creator>张正</dc:creator><dc:creator>萨尔武奇</dc:creator><dc:creator>J瑞</dc:creator><dc:creator>K雷尼尔</dc:creator><dc:creator>党卫军楚格</dc:creator><dc:date>2023-11-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>动态心电图变化是心源性猝死的新风险标志</dc:title><dc:identifier>下午:37956651</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad770</dc:identifier></item><item><title>长房性高频率发作≥24小时的患者使用艾多沙班抗凝</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>结论：这项假设生成分析并未发现，在设备检测到 AHRE 和中风危险因素的患者中，AHRE 持续时间与抗凝治疗之间存在相互作用。需要进一步研究来识别具有高中风风险的长 AHRE 患者。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 12 日：ehad771。doi：10.1093/eurheartj/ehad771。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：长期心房高频率发作（AHRE）≥24小时且有卒中危险因素的患者通常接受抗凝治疗以预防卒中。从未将这些患者的抗凝治疗与不抗凝治疗进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：NOAH-AFNET 6 的二次预先指定分析检查了 AHRE 患者基线 AHRE 持续时间与艾多沙班抗凝治疗与安慰剂相比的相互作用以及中风危险因素。主要疗效结局是中风、全身性栓塞或心血管死亡的综合结果安全性结局是大出血和死亡的综合结果。关键的次要结局是这些结局和心电图诊断的房颤的组成部分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：入组 NOAH-AFNET 6 的 259/2389 名患者（11%，78 ± 7 岁，28% 女性，CHA2DS2-VASc 评分 4）在基线时存在 AHRE ≥24 小时。临床特征与患有以下疾病的患者没有不同：较短的 AHRE。在 1.8 年的中位随访期间，主要结局发生在接受抗凝治疗的 9/132 名 AHRE ≥24 小时的患者（4.3%/患者年，2 次中风）和 14/127 名接受安慰剂治疗的患者中。 （6.9%/患者年，2 次中风）。AHRE 持续时间与抗凝治疗的疗效（p 相互作用 = 0.65）或安全性（p 相互作用 = 0.98）没有相互作用。包括 AHRE 作为连续参数的分析证实了这一点。患者AHRE ≥24 小时的患者比 AHRE 较短的患者（8.2%/患者年；p &lt; 0.001）发生更多心电图诊断的房颤（17.0%/患者年）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项假设生成分析并未发现，在设备检测到 AHRE 和中风危险因素的患者中，AHRE 持续时间与抗凝治疗之间存在相互作用。需要进一步研究来识别具有高中风风险的长 AHRE 患者。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956458</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad771>10.1093/eurheartj/ehad771</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956458</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>尼娜·贝歇尔</dc:creator><dc:creator>托比亚斯·托尼斯</dc:creator><dc:creator>埃马努埃莱·贝尔塔利亚</dc:creator><dc:creator>卡琳娜·布洛姆斯特罗姆-伦奎斯特</dc:creator><dc:creator>阿克塞尔·布兰德斯</dc:creator><dc:creator>努诺·卡巴内拉斯</dc:creator><dc:creator>梅兰妮·卡尔弗特</dc:creator><dc:creator>约翰·卡姆</dc:creator><dc:creator>格雷戈里·克卢韦拉基斯</dc:creator><dc:creator>格奥尔基·安德烈·丹</dc:creator><dc:creator>沃尔夫冈·迪希特尔</dc:creator><dc:creator>汉斯·克里斯托夫·迪纳</dc:creator><dc:creator>亚历山大·费伦茨</dc:creator><dc:creator>安德烈亚斯·戈特</dc:creator><dc:creator>乔里斯·R·德·格鲁特</dc:creator><dc:creator>阿斯特丽德·赫尔曼斯</dc:creator><dc:creator>格雷戈里·YH·利普</dc:creator><dc:creator>安德烈·卢宾斯基</dc:creator><dc:creator>埃洛伊·马里琼</dc:creator><dc:creator>贝拉·默克利</dc:creator><dc:creator>路易斯·蒙</dc:creator><dc:creator>安-凯瑟琳·奥兹加</dc:creator><dc:creator>金·拉贾潘</dc:creator><dc:creator>安德烈·萨科齐</dc:creator><dc:creator>丹尼尔·谢尔</dc:creator><dc:creator>雷纳特·B·施纳贝尔</dc:creator><dc:creator>乌尔里希·肖滕</dc:creator><dc:creator>苏珊·塞纳</dc:creator><dc:creator>伊曼纽尔·西曼蒂拉基斯</dc:creator><dc:creator>帕诺斯·瓦尔达斯</dc:creator><dc:creator>瓦西尔·维尔切夫</dc:creator><dc:creator>丹·威克特尔</dc:creator><dc:creator>安东尼娅·扎普夫</dc:creator><dc:creator>保卢斯·基希霍夫</dc:creator><dc:date>2023-11-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>长房性高频率发作≥24小时的患者使用艾多沙班抗凝</dc:title><dc:identifier>下午:37956458</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad771</dc:identifier></item><item><title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通量</b>。2023 年 11 月 14 日；148(20):e185。doi:10.1161/CIR.0000000000001190。Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956227</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001190>10.1161/CIR.0000000000001190</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956227</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:date> 2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</dc:title><dc:identifier>下午:37956227</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001190</dc:identifier></item><item><title>布鲁格达综合症的风险分层：我们能降到多低？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1556-1558.doi: 10.1161/CIRCULATIONAHA.123.066697.Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956226</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066697>10.1161/CIRCULATIONAHA.123.066697</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956226</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>阿瑟·A·M·王尔德</dc:creator><dc:creator>约翰·赛南</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>布鲁格达综合症的风险分层：我们能降到多低？</dc:title><dc:identifier>下午:37956226</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066697</dc:identifier></item><item><title>张等人关于文章“多梳蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1602-1603. doi: 10.1161/CIRCULATIONAHA.123.066427. Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956225</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066427>10.1161/CIRCULATIONAHA.123.066427</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956225</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>张曼如</dc:creator><dc:creator>郭丹丹</dc:creator><dc:creator>赵晶</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>张等人关于文章“多梳蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信函</dc:title><dc:identifier>下午:37956225</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066427</dc:identifier></item><item><title> Cho 和 Yoon 对有关文章“Polycomb 组蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信件的回应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1604-1605。doi: 10.1161/CIRCULATIONAHA.123.066624。Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956224</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066624>10.1161/CIRCULATIONAHA.123.066624</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956224</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>曹圭元</dc:creator><dc:creator>尹英燮</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>Cho 和 Yoon 对有关文章“Polycomb 组蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信件的回应</dc:title><dc:identifier>下午:37956224</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066624</dc:identifier></item><item><title>使用患者来源的诱导多能干细胞研究由 &lt;em>;NAA10&lt;/em>; 遗传变异引起的长 QT 综合征</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1598-1601. doi: 10.1161/CIRCULATIONAHA.122.061864. Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956223</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061864>10.1161 / CIRCULATIONAHA.122.061864</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956223</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>纳吉特·贝尔巴奇尔</dc:creator><dc:creator>吴一阳</dc:creator><dc:creator>沉梦成</dc:creator><dc:creator>张索菲亚·L</dc:creator><dc:creator>张乔</dc:creator><dc:creator>刘春</dc:creator><dc:creator>比约恩·C·诺尔曼</dc:creator><dc:creator>戈尔森·里昂</dc:creator><dc:creator>马宁</dc:creator><dc:creator>约瑟夫·吴</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>使用患者来源的诱导多能干细胞研究由 &lt;em>;NAA10&lt;/em>; 遗传变异引起的长 QT 综合征</dc:title><dc:identifier>下午:37956223</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.061864</dc:identifier></item><item><title> &lt;em>;流通&lt;/em>;系列期刊的亮点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1593-1597. doi: 10.1161/CIRCULATIONAHA.123.067572. Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956222</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067572>10.1161/循环AHA.123.067572</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956222</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:date> 2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>&lt;em>;流通&lt;/em>;系列期刊的亮点</dc:title><dc:identifier>下午:37956222</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067572</dc:identifier></item><item><title>艾多沙班治疗慢性血栓栓塞性肺动脉高压患者的多中心、单盲、随机、华法林对照试验：KABUKI 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.067528。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37956127</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067528>10.1161/CIRCULATIONAHA.123.067528</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956127</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>细川一也</dc:creator><dc:creator>渡边弘子</dc:creator><dc:creator>谷口佑</dc:creator><dc:creator>池田信孝</dc:creator><dc:creator>稻波匠美</dc:creator><dc:creator>安田聪</dc:creator><dc:creator>室原丰明</dc:creator><dc:creator>波多野胜</dc:creator><dc:creator>田村雄一</dc:creator><dc:creator>山下淳</dc:creator><dc:creator>辰巳光一郎</dc:creator><dc:creator>辻野一三</dc:creator><dc:creator>小早川优子</dc:creator><dc:creator>安达四郎</dc:creator><dc:creator>矢板信宏</dc:creator><dc:creator>水月俊</dc:creator><dc:creator>户高浩二</dc:creator><dc:creator>福田敬一</dc:creator><dc:creator>筒井宏之</dc:creator><dc:creator>阿部光太郎</dc:creator><dc:creator>歌舞伎调查员</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>艾多沙班治疗慢性血栓栓塞性肺动脉高压患者的多中心、单盲、随机、华法林对照试验：KABUKI 试验</dc:title><dc:identifier>下午:37956127</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067528</dc:identifier></item><item><title>托塞米与呋塞米在新发慢性心力衰竭患者与恶化慢性心力衰竭患者中的​​比较：TRANSFORM-HF 随机临床试验的子研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231114090756&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在因 HF 住院后出院的患者中，与 WHF 相比，新发 HF 具有更好的临床和患者报告结果。无论 HF 类型如何，托拉塞米和呋塞米在 12 个月内没有显着差异临床或患者报告的结果。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol.2023 年 11 月 13 日。doi：10.1001/jamacardio.2023.4776。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: Differences in clinical profiles, outcomes, and diuretic treatment effects may exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: To compare clinical characteristics and treatment outcomes of torsemide vs furosemide in patients hospitalized with de novo HF vs WHF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: All patients with a documented ejection fraction who were randomized in the Torsemide Comparison With Furosemide for Management of Heart Failure (TRANSFORM-HF) trial, conducted from June 18 through March 2022, were included in this post hoc analysis. Study data were analyzed March to May 2023. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> EXPOSURE: Patients were categorized by HF type and further divided by loop diuretic strategy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: End points included all-cause mortality and hospitalization outcomes over 12 months, as well as change from baseline in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 2858 patients (mean [SD] age, 64.5 [14.0] years; 1803 male [63.1%]), 838 patients (29.3%) had de novo HF, and 2020 patients (70.7%) had WHF. Patients with de novo HF were younger (mean [SD] age, 60.6 [14.5] years vs 66.1 [13.5] years), had a higher glomerular filtration rate (mean [SD], 68.6 [24.9] vs 57.0 [24.0]), lower levels of natriuretic peptides (median [IQR], brain-type natriuretic peptide, 855.0 [423.0-1555.0] pg/mL vs 1022.0 [500.0-1927.0] pg/mL), and tended to be discharged on lower doses of loop diuretic (mean [SD], 50.3 [46.2] mg vs 63.8 [52.4] mg). De novo HF was associated with lower all-cause mortality at 12 months (de novo, 65 of 838 [9.1%] vs WHF, 408 of 2020 [25.4%]; adjusted hazard ratio [aHR], 0.50; 95% CI, 0.38-0.66; P &lt; .001). Similarly, lower all-cause first rehospitalization at 12 months and greater improvement from baseline in KCCQ-CSS at 12 months were noted among patients with de novo HF (median [IQR]: de novo, 29.94 [27.35-32.54] vs WHF, 23.68 [21.62-25.74]; adjusted estimated difference in means: 6.26; 95% CI, 3.72-8.81; P &lt; .001). There was no significant difference in mortality with torsemide vs furosemide in either de novo (No. of events [rate per 100 patient-years]: torsemide, 27 [7.4%] vs furosemide, 38 [10.9%]; aHR, 0.70; 95% CI, 0.40-1.14; P = .15) or WHF (torsemide 212 [26.8%] vs furosemide, 196 [24.0%]; aHR, 1.08; 95% CI, 0.89-1.32; P = .42; P for interaction = .10), In addition, no significant differences in hospitalizations, first all-cause hospitalization, or total hospitalizations at 12 months were noted with a strategy of torsemide vs furosemide in either de novo HF or WHF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: Among patients discharged after hospitalization for HF, de novo HF was associated with better clinical and patient-reported outcomes when compared with WHF. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37955908</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4776>10.1001/jamacardio.2023.4776</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955908</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Selim R Krim</dc:creator><dc:creator> Senthil Anand</dc:creator><dc:creator> Stephen J Greene</dc:creator><dc:creator> Anqi Chen</dc:creator><dc:creator> Daniel Wojdyla</dc:creator><dc:creator> Juan Vilaro</dc:creator><dc:creator> Herbert Haught</dc:creator><dc:creator> John M Herre</dc:creator><dc:creator> Eric L Eisenstein</dc:creator><dc:creator> Kevin J Anstrom</dc:creator><dc:creator> Bertram Pitt</dc:creator><dc:creator> Eric J Velazquez</dc:creator><dc:creator> Robert J Mentz</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial</dc:title><dc:identifier> pmid:37955908</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4776</dc:identifier></item><item><title> Neighborhood Environmental Burden and Cardiovascular Health in the US</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114090756&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS AND RELEVANCE: In this cross-sectional study of US neighborhoods, cumulative environmental burden was associated with higher rates of cardiovascular risk factors and diseases, although absolute differences were small. The strongest associations were observed in socially vulnerable neighborhoods. Whether initiatives that address poor environmental conditions will improve cardiovascular health requires additional prospective investigations. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Nov 13. doi: 10.1001/jamacardio.2023.4680. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: Cardiovascular disease is the leading cause of death in the US. However, little is known about the association between cumulative environmental burden and cardiovascular health across US neighborhoods. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To evaluate the association of neighborhood-level environmental burden with prevalence of cardiovascular risk factors and diseases, overall and by levels of social vulnerability. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTINGS, AND PARTICIPANTS: This was a national cross-sectional study of 71 659 US Census tracts. Environmental burden (EBI) and social vulnerability indices from the US Centers for Disease Control and Prevention (CDC) and Agency for Toxic Substances and Disease Registry were linked to the 2020 CDC PLACES data set. Data were analyzed from March to October 2023. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> EXPOSURES: The EBI, a measure of cumulative environmental burden encompassing 5 domains (air pollution, hazardous or toxic sites, built environment, transportation infrastructure, and water pollution). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: Neighborhood-level prevalence of cardiovascular risk factors (hypertension, diabetes, and obesity) and cardiovascular diseases (coronary heart disease and stroke). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Across the US, neighborhoods with the highest environmental burden (top EBI quartile) were more likely than those with the lowest environmental burden (bottom EBI quartile) to be urban (16 626 [92.7%] vs 13 414 [75.4%]), in the Midwest (5191 [28.9%] vs 2782 [15.6%]), have greater median (IQR) social vulnerability scores (0.64 [0.36-0.85] vs 0.42 [0.20-0.65]), and have higher proportions of adults in racial or ethnic minority groups (median [IQR], 34% [12-73] vs 12% [5-30]). After adjustment, neighborhoods with the highest environmental burden had significantly higher rates of cardiovascular risk factors than those with the lowest burden, including hypertension (mean [SD], 32.83% [7.99] vs 32.14% [6.99]; adjusted difference, 0.84%; 95% CI, 0.71-0.98), diabetes (mean [SD], 12.19% [4.33] vs 10.68% [3.27]; adjusted difference, 0.62%; 95% CI, 0.53-0.70), and obesity (mean [SD], 33.57% [7.62] vs 30.86% [6.15]; adjusted difference, 0.77%; 95% CI, 0.60-0.94). Similarly, neighborhoods with the highest environmental burden had significantly higher rates of coronary heart disease (mean [SD], 6.66% [2.15] vs 6.82% [2.41]; adjusted difference, 0.28%; 95% CI, 0.22-0.33) and stroke (mean [SD], 3.65% [1.47] vs 3.31% [1.12]; adjusted difference, 0.19%; 95% CI, 0.15-0.22). Results were consistent after matching highest and lowest environmentally burdened neighborhoods geospatially and based on other covariates. The associations between environmental burden quartiles and cardiovascular risk factors and diseases were most pronounced among socially vulnerable neighborhoods. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: In this cross-sectional study of US neighborhoods, cumulative environmental burden was associated with higher rates of cardiovascular risk factors and diseases, although absolute differences were small. The strongest associations were observed in socially vulnerable neighborhoods. Whether initiatives that address poor environmental conditions will improve cardiovascular health requires additional prospective investigations.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37955891</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4680>10.1001/jamacardio.2023.4680</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955891</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Michael Liu</dc:creator><dc:creator> Vishal R Patel</dc:creator><dc:creator> Renee N Salas</dc:creator><dc:creator> Mary B Rice</dc:creator><dc:creator> Dhruv S Kazi</dc:creator><dc:creator> ZhaoNian Zheng</dc:creator><dc:creator> Rishi K Wadhera</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Neighborhood Environmental Burden and Cardiovascular Health in the US</dc:title><dc:identifier> pmid:37955891</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4680</dc:identifier></item><item><title> Prioritizing the Exposome to Reduce Cardiovascular Disease Burden</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114090756&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Nov 13. doi: 10.1001/jamacardio.2023.4722. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37955872</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4722>10.1001/jamacardio.2023.4722</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955872</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Erica S Spatz</dc:creator><dc:creator> Kai Chen</dc:creator><dc:creator> Harlan M Krumholz</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Prioritizing the Exposome to Reduce Cardiovascular Disease Burden</dc:title><dc:identifier> pmid:37955872</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4722</dc:identifier></item><item><title> Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114090756&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067588. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37955620</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067588>10.1161/CIRCULATIONAHA.123.067588</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955620</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> David J Whellan</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation</dc:source><dc:title> Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume</dc:title><dc:identifier> pmid:37955620</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067588</dc:identifier></item><item><title> Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114090756&amp;v=2.17.9.post6+86293ac<description> Background: Physical activity is pivotal in managing heart failure with reduced ejection fraction (HFrEF), and walking integrated into daily life is an especially suitable form of such physical activity. This study aimed to determine if a 6-month lifestyle walking intervention combining self-monitoring and regular phone counseling improves functional capacity assessed by the six-minute walk test (6MWT) in stable patients with HFrEF compared to usual care. Methods: The WATCHFUL trial was a... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067395. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Physical activity is pivotal in managing heart failure with reduced ejection fraction (HFrEF), and walking integrated into daily life is an especially suitable form of such physical activity. This study aimed to determine if a 6-month lifestyle walking intervention combining self-monitoring and regular phone counseling improves functional capacity assessed by the six-minute walk test (6MWT) in stable patients with HFrEF compared to usual care. <b>Methods:</b> The WATCHFUL trial was a 6-month, multicenter, parallel-group, randomized, controlled trial recruiting HFrEF patients from six Czech cardiovascular centers. Eligible participants were ≥18 years old with left ventricular ejection fraction &lt;40% and NYHA class II/III symptoms, on guidelines-recommended medication, excluding those exceeding 450m in the baseline 6MWT. Patients in the intervention group were equipped with a Garmin vívofit activity tracker and received monthly phone counseling from research nurses who encouraged them to employ behavior change techniques such as self-monitoring, goal-setting, and action planning to increase their daily step count. The control group patients continued usual care. The primary outcome was the difference between groups in the distance (in meters) walked during the 6MWT at 6 months. Secondary outcomes included daily step count and minutes of moderate-to-vigorous physical activity (MVPA) as measured by the hip-worn Actigraph wGT3X-BT accelerometer, NT-proBNP and hsCRP biomarkers, ejection fraction, anthropometric measures, depression score, self-efficacy, quality of life, and survival risk score. The primary analysis was conducted by intention-to-treat. <b>Results:</b> From 218 screened patients, 202 were randomized (65 years; 22.8% female; 90.6% NYHA II; left ventricular ejection fraction 32.5%; 6MWT 385m; 5071 steps/day; 10.9 minutes of MVPA per day). At six months, no between-group differences were detected for the 6MWT (7.4 m, 95% CI -8.0 to 22.7, p=0.345, N=186). The intervention group increased their average daily step count by 1420 (95% CI: 749; 2091) and daily minutes of MVPA by 8.2 (95% CI: 3.0; 13.3) over the control group. No between-group differences were detected for any other secondary outcomes. <b>Conclusions:</b> While the lifestyle intervention in patients with HFrEF improved daily steps by about 25%, it failed to demonstrate a corresponding improvement in functional capacity. Further research is needed to understand the disconnect between increased physical activity and functional outcomes.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37955615</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067395>10.1161/CIRCULATIONAHA.123.067395</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955615</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Tomas Vetrovsky</dc:creator><dc:creator> Michal Siranec</dc:creator><dc:creator> Tereza Frybova</dc:creator><dc:creator> Iulian Gant</dc:creator><dc:creator> Iveta Svobodova</dc:creator><dc:creator> Ales Linhart</dc:creator><dc:creator> Jiri Parenica</dc:creator><dc:creator> Marie Miklikova</dc:creator><dc:creator> Lenka Sujakova</dc:creator><dc:creator> David Pospisil</dc:creator><dc:creator> Radek Pelouch</dc:creator><dc:creator> Daniela Odrazkova</dc:creator><dc:creator> Petr Parizek</dc:creator><dc:creator> Jan Precek</dc:creator><dc:creator> Martin Hutyra</dc:creator><dc:creator> Milos Taborsky</dc:creator><dc:creator> Jiri Vesely</dc:creator><dc:creator> Martin Griva</dc:creator><dc:creator> Miroslav Semerad</dc:creator><dc:creator> Vaclav Bunc</dc:creator><dc:creator> Karolina Hrabcova</dc:creator><dc:creator> Adela Vojkuvkova</dc:creator><dc:creator> Michal Svoboda</dc:creator><dc:creator> Jan Belohlavek</dc:creator><dc:creator> WATCHFUL Investigators</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation</dc:source><dc:title> Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial</dc:title><dc:identifier> pmid:37955615</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067395</dc:identifier></item><item><title> Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114090756&amp;v=2.17.9.post6+86293ac<description> Background: Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies. Methods: This study included National Collegiate Athletic Association athlete deaths during a 20-year time frame (July 1, 2002, through June 30, 2022). Athlete deaths were identified through 4 separate independent databases and search strategies (National Collegiate Athletic Association resolutions list, Parent Heart Watch database... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.065908. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies. <b>Methods:</b> This study included National Collegiate Athletic Association athlete deaths during a 20-year time frame (July 1, 2002, through June 30, 2022). Athlete deaths were identified through 4 separate independent databases and search strategies (National Collegiate Athletic Association resolutions list, Parent Heart Watch database and media reports, National Center for Catastrophic Sports Injury Research database, and insurance claims). Autopsy reports and medical history were reviewed by an expert panel to adjudicate causes of SCD. <b>Results:</b> A total of 143 SCD cases in National Collegiate Athletic Association athletes were identified from 1102 total deaths. The National Collegiate Athletic Association resolutions list identified 117 of 143 (82%), the Parent Heart Watch database or media reports identified 89 of 143 (62%), the National Center for Catastrophic Sports Injury Research database identified 63 of 143 (44%), and insurance claims identified 27 of 143 (19%) SCD cases. The overall incidence of SCD was 1:63682 athlete-years (95% CI, 1:54065-1:75010). Incidence was higher in male athletes than in female athletes (1:43348 [95% CI, 1:36228-1:51867] versus 1:164504 [95% CI, 1:110552-1:244787] athlete-years, respectively) and Black athletes compared with White athletes (1:26704 [1:20417-1:34925] versus 1:74581 [1:60247-1:92326] athlete-years, respectively). The highest incidence of SCD was among Division I male basketball players (1:8188 [White, 1:5848; Black, 1:7696 athlete-years]). The incidence rate for SCD decreased over the study period (5-year incidence rate ratio, 0.71 [95% CI, 0.61-0.82]), whereas the rate of noncardiovascular deaths remained stable (5-year incidence rate ratio, 0.98 [95% CI, 0.94-1.04]). Autopsy-negative sudden unexplained death (19.5%) was the most common postmortem examination finding, followed by idiopathic left ventricular hypertrophy or possible cardiomyopathy (16.9%) and hypertrophic cardiomyopathy (12.7%), in cases with enough information for adjudication (118 of 143). Eight cases of death were attributable to myocarditis over the study period (1 case from January 1, 2020, through June 30, 2022), with none attributed to COVID-19 infection. SCD events were exertional in 50% of cases. Exertional SCD was more common among those with coronary artery anomalies (100%) and arrhythmogenic cardiomyopathy (83%). <b>Conclusions:</b> The incidence of SCD in college athletes has decreased. Male sex, Black race, and basketball are associated with a higher incidence of SCD.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114090756&v=2.17.9.post6+86293ac">37955565</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065908>10.1161/CIRCULATIONAHA.123.065908</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955565</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Bradley J Petek</dc:creator><dc:creator> Timothy W Churchill</dc:creator><dc:creator> Nathaniel Moulson</dc:creator><dc:creator> Stephanie A Kliethermes</dc:creator><dc:creator> Aaron L Baggish</dc:creator><dc:creator> Jonathan A Drezner</dc:creator><dc:creator> Manesh R Patel</dc:creator><dc:creator> Michael J Ackerman</dc:creator><dc:creator> Kristen L Kucera</dc:creator><dc:creator> David M Siebert</dc:creator><dc:creator> Lauren Salerno</dc:creator><dc:creator> Monica Zigman Suchsland</dc:creator><dc:creator> Irfan M Asif</dc:creator><dc:creator> Joseph J Maleszewski</dc:creator><dc:creator> Kimberly G Harmon</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation</dc:source><dc:title> Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study</dc:title><dc:identifier> pmid:37955565</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065908</dc:identifier></item></channel></rss>